Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
Key Clinical Message Philadelphia‐negative (Ph−) myeloproliferative neoplasms (MPN) do rarely transform to acute lymphoblastic leukemia (ALL). While causality is difficult to establish, a few cases of ALL arising after exposure to lenalidomide for registered indications (multiple myeloma, myelodysplastic syndrome with 5q deletion) have been described in the literature. Philadelphia‐negative (Ph−) myeloproliferative neoplasms (MPN) do rarely transform to acute lymphoblastic leukemia (ALL). While causality is difficult to establish, a few cases of ALL arising after exposure to lenalidomide for registered indications (multiple myeloma, myelodysplastic syndrome with 5q deletion) have been described in the literature.
We report a case of myeloid sarcoma that developed in the primary tumor lymphatic drainage field of a previously treated intermediate-thickness cutaneous melanoma, clinically and radiographically mimicking an in-transit metastasis, in a patient with myelodysplastic syndrome. The diagnosis of myeloid sarcoma was achieved after surgical excision of the mass and pathological examination that included extensive immunohistochemical studies. Awareness of such an unusual clinical presentation can help reduce diagnostic delay and ensure that adequate tissue is obtained for pathological examination and ancillary studies that are cr...
CONCLUSION: Besides screening for clonal lymphocytes, plasma cells and blasts, an LST supplemented with CD34 allows the calculation of the Ogata score as an adjuvant tool in the diagnostic workup of cytopenic patients suspected of MDS. PMID: 30334700 [PubMed - as supplied by publisher]
CONCLUSION: A better understanding of the immune dysregulation triggered by LGL leukemia will be beneficial to explore the pathogenesis and potential therapeutic targets for this disease. PMID: 30334691 [PubMed - as supplied by publisher]
Authors: Sachiyo O, Masahiro T, Tsutomu T, Makoto I, Yutaka H, Nobumasa M, Takamichi K, Nozomi O, Shinpei M, Kazuhiro T, Yusuke K, Masanori O, Yusuke K, Yasuhisa H, Kazuo H, Yasumasa N Abstract Fanconi anemia (FA) is a disorder of chromosomal fragility characterized by progression to aplastic anemia, myelodysplastic syndrome, and leukemia. FA patients are also predisposed to solid cancers. A case of FA in an adult patient who developed tongue and superficial esophageal cancers following hematopoietic stem cell transplantation is reported. This case was considered significant because it is the first reported case of...
ConclusionsThe overexpression of endogenous protein inhibitors of PP2A, SET and CIP2A, is tightly linked to the progression of various human cancers, as well as Alzheimer ’s disease.
I realize it’s been quite some TIME since I’ve written a post, almost a MONTH!, so today I decided to sit down and write one, and it’s going to be a long one, so get yourselves some tea and get comfy… CHAPTER ONE. PEEKABOO: in September I spent a lot of time researching possibly helpful but definitely non-toxic treatments for Peekaboo, my 11-year-old kitty whom I’ve written a lot about in recent times. She has a slipped disc, basically, and has been having a VERY hard time walking. The risk, of course, is that she’d stop walking altogether. Couldn’t let that happen! I...
ConclusionsPrompt and appropriate laboratory investigations ensure correct diagnosis of pseudohyperphosphatemia and help clinicians properly manage patients. To our knowledge, this patient is the first reported case of pseudohyperphosphatemia in patients with progression from SMM to MM.
Condition: Multiple Myeloma Intervention: Biological: IM21 CART Sponsors: Peking Union Medical College Hospital; Beijing Immunochina Medical Science&Technology Co., Ltd. Recruiting
Condition: Refractory Plasma Cell Myeloma Interventions: Drug: Dexamethasone; Biological: Elotuzumab; Drug: Pomalidomide Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting